Title
Author
DOI
Article Type
Special Issue
Volume
Issue
Does the localisation of tumour at Stage I endometrial endometrioid adenocarcinoma have an impact on invasion of the tumour and individualisation of the surgical procedure?
1Department of Obstetrics and Gynecology, Mersin University, Turkey
2Department of Obstetrics and Gynecology, Gulhane Military Medical Academy, Turkey
3Department of Pathology, Gulhane Military Medical Academy, Turkey
4Department of Obstetrics and Gynecology, Süleyman Demirel University,Turkey
5Gynecologic Oncology Unit, Women’s Health Education and Research Hospital, Zekai Tahir Burak (ZTB), Turkey
*Corresponding Author(s): K. Gezginç E-mail: kazimgezginc@hotmail.com
Objective: To detect whether the localisation of the tumour has an impact on the dissemination of the tumour and whether or not surgical procedures should be individualized according to the localisation of the tumour. Material Method: 106 clinically surgically stage I endometrial endometrioid carcinoma cases treated multi-institutionally at Gulhane Military Medical Academy (GATA) and Dr. Zekai Tahir Burak (ZTB) Women's Health Education and Research Hospital Gynecologic Oncology Units in the last five years were evaluated retrospectively. The tumours localised near the internal cervical os and not invading the cervical canal were accepted as lower uterine segment (LUS) localisation and the corporal location as upper uterine segment (UUS) localisation. Results: Tumour localisation was more frequent in the upper segment than LUS (85.9% vs 14.1%). There was no statistically significant difference between only endometrial and only serous invasion rates. Myometrial invasion less than one-half was significantly higher in the UUS group than the LUS group (p < 0.05). Lymph vascular space involvement rate was significantly higher in the LUS group (60%, 9/15) than the UUS group (23 %, 21/91), (p < 0.01). Positive peritoneal cytology rate was 20% (3/15) in the LUS group and 6.6% (6/91) in the UUS group (p > 0.05). Conclusion: Patients with LUS involvement should be considered as high-risk patients. Thus more expanded surgery must be taken into consideration. In this study a limitation was the low number of patients with LUS involvement. Larger prospective studies are necessary to confirm our results.
Endometrial cancer, Tumour invasion, Surgical procedure
S. Dilek,M. Dede,K. Gezginç,M.C. Yenen,Ü. Göktolga,H.C. Ulutin,M.S. Deveci,E. Erdemoglu,T. Aydogdu. Does the localisation of tumour at Stage I endometrial endometrioid adenocarcinoma have an impact on invasion of the tumour and individualisation of the surgical procedure?. European Journal of Gynaecological Oncology. 2008. 29(2);138-140.
[1] Pecorelli S.: “FIGO Annual Report, years 1990-1992”. J. Epidemiol. Biostat., 1998, 3, 41.
[2] Creasman W.T., Morrow C.P., Bundy L.: “Surgical pathological spread patterns of endometrial cancer”. Cancer, 1987, 60, 2035.
[3] Lampe B., Kurz I.L., Hantschman P.: “Reliability of tumor typing of endometrial carcinoma in prehysterectomy curettage”. Int. J. Gynecol. Pathol., 1995, 14, 2.
[4] Zaine R.J., Kurman R.J.: “Squamous differentiation in carcinoma of endometrium: A critical appraisal of adenoachantoma and adenosquamous carcinoma”. Semin. Diagn. Pathol., 1988, 5, 14.
[5] Zaine R.J., Silverberg S.G., Norris H.S.: “The prognostic value of nuclear versus architectural grading in endometrial adenocarcinoma. A Gynecologic Oncology Group Study”. Int. J. Gynecol. Pathol., 1994, 13, 29.
[6] Barakat R.R.: “Contemporary issues in the management of endometrial cancer”. CA Cancer J. Clin., 1998, 48, 299.
[7] Hendrickson M., Kempson R.: “Surgical pathology of the uterine corpus”. Philadelphia, WB Saunders, 1980, 36.
[8] Doering D.L., Bornhill D.R., Weiser E.B.: “Intraoperative evaluation of depth of myometrial invasion in stage I endometrial adenocarcinoma”. Obstet. Gynecol., 1989, 74, 930.
[9] Wharton J.T., Mikuta J.J., Mettlin C.: “Risk factors and current management in carcinoma of the endometrium”. Surg. Gynecol. Obstet., 1986, 162, 215.
[10] Sutton G.P., Geiser H.E., Stehman F.B.: “Features associated with survival and disease free survival in early endometrial cancer”. Am. J. Obstet. Gynecol., 1989, 160, 1385.
[11] Silverberg S.G., Kurman R.J.: “Tumors of the uterine corpus and gestational trophoblastic disease”. In: Atlas of tumor pathology. Third series. Washington D.C. Armed Forces Institute of Pathology, 1992, 487.
[12] Chambers S.K., Kall D.S., Peschel R.E.: “Prognostic factors and sides of failure in FIGO Stage I Grade 3 endometrial carcinoma”. Gynecol. Oncol., 1987, 27, 180.
[13] Watanabe Y., Nakasima H., Nazaki K., Ueda H., Obata K., Hashia H. et al.: “Clinicopathlogic and immunohistochemical features and microsatellite status of endometrial cancer of uterine isthmus”. Int. J. Gynecol. Pathol., 2001, 368, 73.
[14] Barakat R.R., Park R.C., Grigsby P.W., Muss H.D., Norris H.J.: “Corpus: epithelial tumors”. In: Hoskins W.J., Perez C.A., Young R.C. (eds.). “Principles and Practice of Gynecologic Oncology” 2nd edn., Philadelphia, Lippincott, 1997, 859.
[15] Grigsby P.W., Perez C.A., Kuten A.: “Clinical Stage I Endometrial cancer: prognostic factors for local control and distant metastasis and implications of the new FIGO surgical staging system”. Int. Radiat. Oncol. Biol. Phys., 1992, 22, 905.
[16] Irwin C., Lewin W., Fyles A.: “The role of adjuvant radiotherapy in carcinoma of the endometrium results in 550 patients with pathologic stage I disease”. Gynecol. Oncol., 1998, 70, 247.
[17] Hachisuga T., Kaku T., Empoji M.: “Carcinoma of the lower uterine segment clinicopathologic analysis of 12 cases”. Int. J. Gynecol. Pathol., 1989, 8, 26.
[18] Jiko K., Tsuda H., Sato S., Hirohashi S.: “Pathogenic significance of p53 and c-Ki-ras gene mutations and human papillomavirus DNA integration in adenocarcinoma of the uterine isthmus”. Int. J. Cancer, 1994, 59, 601.
[19] Mayr N.A., Wen B.C., Benda J.A.: “Postoperative radiation therapy in clinical Stage I endometrial cancer. Corpus, cervical and lower uterine segment involvement patterns of failure”. Radiology, 1995, 196, 323.
[20] Disaia P.J., Creasman W.T., Boronow R.C.: “Risk factors and recurrent patterns in stage I Endometrial cancer”. Am. J. Obstet. Gynecol., 1985, 151, 1009.
[21] Morrow C.P., Bandy B.N., Kurman R.J.: “Relationship between surgical-pathological risk factors and outcome in clinical Stage I and II carcinoma of the endometrium: A GOG study”. Gynecol. Oncol., 1991, 40, 55.
[22] Zaino R.J., Kurman R.J., Diana K.L., Morrow C.P.: “Pathologic models to predict outcome for women with Endometrial adenocarcinomas: The importance of the distinction between surgical stage and clinical stage: A GOG study”. Cancer, 1996, 77, 1115.
[23] Phelan C., Montag G.A., Rotmensch J., Waggoner S.E., Yamada S.D., Mundt A.: “Outcome and management of pathological Stage I endometrial carcinoma patients with involvement of the lower uterine segment”. Gynecol. Oncol., 2001, 83, 513.
Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.
Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.
JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.
Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.
BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.
Top